Esphera SynBio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $2M

  • Investors
  • 4

Esphera SynBio General Information

Description

Operator of a biotechnology company intended to develop cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through its proprietary transgene technology, enabling pharmaceutical companies to focus on enhancing mRNA vaccine efficacy for infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Ottawa, Ontario
  • Canada
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Ottawa, Ontario
  • Canada

Esphera SynBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Esphera SynBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 07-Jan-2025 $2M Completed Generating Revenue
2. Seed Round 24-Aug-2023 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Esphera SynBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Esphera SynBio Patents

Esphera SynBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025251149-A1 Self-adjuvanting vesicular vaccine Pending 03-Jun-2024

Esphera SynBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Esphera SynBio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
FACIT Venture Capital Minority
GKCC Venture Capital Minority
McMaster University University
Capital BioVentures Accelerator/Incubator Minority
To view Esphera SynBio’s complete investors history, request access »

Esphera SynBio FAQs

  • When was Esphera SynBio founded?

    Esphera SynBio was founded in 2022.

  • Where is Esphera SynBio headquartered?

    Esphera SynBio is headquartered in Ottawa, Canada.

  • What is the size of Esphera SynBio?

    Esphera SynBio has 10 total employees.

  • What industry is Esphera SynBio in?

    Esphera SynBio’s primary industry is Biotechnology.

  • Is Esphera SynBio a private or public company?

    Esphera SynBio is a Private company.

  • What is Esphera SynBio’s current revenue?

    The current revenue for Esphera SynBio is .

  • How much funding has Esphera SynBio raised over time?

    Esphera SynBio has raised $2.26M.

  • Who are Esphera SynBio’s investors?

    FACIT, GKCC, McMaster University, and Capital BioVentures have invested in Esphera SynBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process